Browse EOMES

Summary
SymbolEOMES
Nameeomesodermin
Aliases TBR2; T-box brain2; eomesodermin (Xenopus laevis) homolog; T-box brain protein 2; TBR-2; T-brain-2; Eomesode ......
Chromosomal Location3p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00907 T-box
PF16176 T-box transcription factor-associated
Function

Functions as a transcriptional activator playing a crucial role during development. Functions in trophoblast differentiation and later in gastrulation, regulating both mesoderm delamination and endoderm specification. Plays a role in brain development being required for the specification and the proliferation of the intermediate progenitor cells and their progeny in the cerebral cortex. Also involved in the differentiation of CD8+ T-cells during immune response regulating the expression of lytic effector genes.

> Gene Ontology
 
Biological Process GO:0001701 in utero embryonic development
GO:0001704 formation of primary germ layer
GO:0001706 endoderm formation
GO:0001707 mesoderm formation
GO:0001708 cell fate specification
GO:0001711 endodermal cell fate commitment
GO:0001714 endodermal cell fate specification
GO:0001824 blastocyst development
GO:0001825 blastocyst formation
GO:0001829 trophectodermal cell differentiation
GO:0001837 epithelial to mesenchymal transition
GO:0001890 placenta development
GO:0001892 embryonic placenta development
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002287 alpha-beta T cell activation involved in immune response
GO:0002292 T cell differentiation involved in immune response
GO:0002293 alpha-beta T cell differentiation involved in immune response
GO:0002302 CD8-positive, alpha-beta T cell differentiation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002521 leukocyte differentiation
GO:0003002 regionalization
GO:0007159 leukocyte cell-cell adhesion
GO:0007369 gastrulation
GO:0007389 pattern specification process
GO:0007492 endoderm development
GO:0007498 mesoderm development
GO:0007507 heart development
GO:0007517 muscle organ development
GO:0007519 skeletal muscle tissue development
GO:0010002 cardioblast differentiation
GO:0014706 striated muscle tissue development
GO:0019827 stem cell population maintenance
GO:0021537 telencephalon development
GO:0021543 pallium development
GO:0021772 olfactory bulb development
GO:0021796 cerebral cortex regionalization
GO:0021871 forebrain regionalization
GO:0021895 cerebral cortex neuron differentiation
GO:0021953 central nervous system neuron differentiation
GO:0021978 telencephalon regionalization
GO:0021987 cerebral cortex development
GO:0021988 olfactory lobe development
GO:0030098 lymphocyte differentiation
GO:0030217 T cell differentiation
GO:0030900 forebrain development
GO:0032609 interferon-gamma production
GO:0035051 cardiocyte differentiation
GO:0035914 skeletal muscle cell differentiation
GO:0035987 endodermal cell differentiation
GO:0036037 CD8-positive, alpha-beta T cell activation
GO:0042110 T cell activation
GO:0043374 CD8-positive, alpha-beta T cell differentiation
GO:0045165 cell fate commitment
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0048332 mesoderm morphogenesis
GO:0048568 embryonic organ development
GO:0048608 reproductive structure development
GO:0048762 mesenchymal cell differentiation
GO:0048863 stem cell differentiation
GO:0060485 mesenchyme development
GO:0060537 muscle tissue development
GO:0060538 skeletal muscle organ development
GO:0060706 cell differentiation involved in embryonic placenta development
GO:0060795 cell fate commitment involved in formation of primary germ layer
GO:0060809 mesodermal to mesenchymal transition involved in gastrulation
GO:0061458 reproductive system development
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071593 lymphocyte aggregation
GO:0098727 maintenance of cell number
Molecular Function GO:0001076 transcription factor activity, RNA polymerase II transcription factor binding
GO:0001085 RNA polymerase II transcription factor binding
GO:0001102 RNA polymerase II activating transcription factor binding
GO:0001191 transcriptional repressor activity, RNA polymerase II transcription factor binding
GO:0003682 chromatin binding
GO:0008134 transcription factor binding
GO:0033613 activating transcription factor binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1266738: Developmental Biology
R-HSA-2892245: POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation
R-HSA-452723: Transcriptional regulation of pluripotent stem cells
Summary
SymbolEOMES
Nameeomesodermin
Aliases TBR2; T-box brain2; eomesodermin (Xenopus laevis) homolog; T-box brain protein 2; TBR-2; T-brain-2; Eomesode ......
Chromosomal Location3p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EOMES and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between EOMES and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
22544698LymphomaPromote immunity (NK cell function)Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells.
27775550Acute myeloid leukemiaPromote immunityIndeed, NK cells from leukemic mice and humans with AML showed lower levels of TBET and EOMES, transcription factors that are critical for terminal NK cell differentiation.
19688743MelanomaPromote immunity (T cell function)Gadd45b, a signaling molecule highly up-regulated during Th1 type responses, is studied for its role in limiting tumor growth. Mouse B16 melanoma cells implanted into Gadd45b(-/-) mice grew faster than those in WT or Gadd45b(+/-) littermate controls. The defect of Gadd45b(-/-) mice in tumor immunosurveillance was attributed to the reduced expression of IFN-gamma, granzyme B, and CCR5 in Gadd45b(-/-) CD8(+) T cells at the tumor site. Activation of p38 MAP kinase, but not ERK or JNK, by either TCR-stimuli or IL-12 and IL-18 is diminished in Gadd45b(-/-) CD8(+) T cells, resulting in reduced production of IFN-gamma. In addition, mRNA of T-bet and Eomes were reduced in Gadd45b(-/-) CD8(+) T cells, supporting a critical role of Gadd45b in shaping the Th1 fate.
20713880MelanomaPromote immunity (infiltration)In this paper, we show that the combined germline deletion of T-bet and T cell-specific deletion of Eomes resulted in profound defects in adaptive antitumor immune responses. T-bet and Eomes drive Tc1 differentiation by preventing alternative CD8(+) T cell differentiation to Tc17 or Tc2 cells. Surprisingly, T-bet and Eomes are not critical for the generation of systemic CTL activities against cancer cells. Instead, T-bet and Eomes are crucial for tumor infiltration by CD8(+) T cells.
18523263MelanomaPromote immunityAntitumor responses depend on type 1 immunity, which is severely impaired in mice deficient for the T-box expressed in T cells (T-bet) transcription factor. Both T-bet-deficient (T-bet(-/-)) NK and CTL show defective function, which can be overcome by strong stimuli due to the expression of eomesodermin, another member of the T-box family.
20525896MelanomaPromote immunity (T cell function)Naturally activated V gamma 4 gamma delta T cells play a protective role in tumor immunity through expression of eomesodermin. Indeed, CD44(high) Vgamma4 gammadelta T cells produced significantly more IFN-gamma and perforin on activation, and showed greater cytolytic activity than did CD44(high) Vgamma1 gammadelta T cells, apparently due to the high level of eomesodermin (Eomes) in these activated Vgamma4 gammadelta T cells. Consistently, transfection of dominant-negative Eomes in Vgamma4 gammadelta T cells diminished the level of IFN-gamma secretion, indicating a critical role of Eomes in the effector function of these gammadelta T cells.
Summary
SymbolEOMES
Nameeomesodermin
Aliases TBR2; T-box brain2; eomesodermin (Xenopus laevis) homolog; T-box brain protein 2; TBR-2; T-brain-2; Eomesode ......
Chromosomal Location3p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EOMES in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolEOMES
Nameeomesodermin
Aliases TBR2; T-box brain2; eomesodermin (Xenopus laevis) homolog; T-box brain protein 2; TBR-2; T-brain-2; Eomesode ......
Chromosomal Location3p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EOMES in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1790.696
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.8790.392
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3260.663
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2810.603
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6640.542
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2010.878
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4020.372
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7380.416
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0670.951
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.0020.286
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4280.751
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.4070.103
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of EOMES in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.75.5-1.81
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.76.8-3.11
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolEOMES
Nameeomesodermin
Aliases TBR2; T-box brain2; eomesodermin (Xenopus laevis) homolog; T-box brain protein 2; TBR-2; T-brain-2; Eomesode ......
Chromosomal Location3p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EOMES. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEOMES
Nameeomesodermin
Aliases TBR2; T-box brain2; eomesodermin (Xenopus laevis) homolog; T-box brain protein 2; TBR-2; T-brain-2; Eomesode ......
Chromosomal Location3p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EOMES. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EOMES.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEOMES
Nameeomesodermin
Aliases TBR2; T-box brain2; eomesodermin (Xenopus laevis) homolog; T-box brain protein 2; TBR-2; T-brain-2; Eomesode ......
Chromosomal Location3p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EOMES. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEOMES
Nameeomesodermin
Aliases TBR2; T-box brain2; eomesodermin (Xenopus laevis) homolog; T-box brain protein 2; TBR-2; T-brain-2; Eomesode ......
Chromosomal Location3p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EOMES expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEOMES
Nameeomesodermin
Aliases TBR2; T-box brain2; eomesodermin (Xenopus laevis) homolog; T-box brain protein 2; TBR-2; T-brain-2; Eomesode ......
Chromosomal Location3p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EOMES and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEOMES
Nameeomesodermin
Aliases TBR2; T-box brain2; eomesodermin (Xenopus laevis) homolog; T-box brain protein 2; TBR-2; T-brain-2; Eomesode ......
Chromosomal Location3p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EOMES collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.